Nutriband's Trademark Acquisition and its Significance
Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a pioneer in transdermal pharmaceutical products, has recently achieved a vital milestone by obtaining the Certificate of Registration from the United States Patent and Trademark Office (USPTO). This important registration for the trademark "Nutriband™" reflects the company’s commitment to innovation in the pharmaceutical industry.
The Importance of the Nutriband™ Trademark
The trademark registration number 7,692,920 is not just a formal recognition; it is a strategic asset for Nutriband. By protecting the Nutriband name, the company enhances its platform technology, particularly its flagship product, AVERSA™. This technology is specially designed to integrate into transdermal patches, tackling the global issue of drug abuse by mitigating risks like misuse and accidental exposure.
Understanding AVERSA™ Technology
The AVERSA™ system incorporates aversive agents, creating a deterrent for potential abusers. While it allows patients to access critical medications safely, it also ensures drugs like fentanyl, known for their high abuse potential, are less prone to misuse. With a robust intellectual property portfolio, Nutriband is positioned favorably within the pharma landscape, having secured patents not only in the United States but also across multiple countries, including Europe, Canada, and Australia.
Progress in Product Development
Nutriband is actively collaborating with Kindeva Drug Delivery to refine manufacturing processes for AVERSA™ Fentanyl, which is on track for FDA approval soon. This product aims to revolutionize the market for abuse deterrent pharmaceuticals, reflecting Nutriband's dedication to developing safer medication methods.
Market Potential and Future Prospects
A recent market analysis report from Health Advances indicates that AVERSA™ Fentanyl could achieve peak annual sales in the United States ranging between $80 million to $200 million. This data underscores the substantial impact AVERSA™ could have on the marketplace, addressing a critical need for effective abuse deterrent options.
About Nutriband Inc.
Nutriband Inc. is at the forefront of developing a portfolio of transdermal pharmaceutical products. Its commitment to safety and innovation continues to drive its initiatives, particularly with their abuse deterrent fentanyl patch that employs AVERSA™ technology. This approach emphasizes the prevention of abuse and enhances drug delivery's overall safety profile.
Contact Information
For further inquiries, Nutriband can be reached at:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
Frequently Asked Questions
What is AVERSA™ technology?
AVERSA™ is Nutriband's abuse deterrent technology designed to incorporate aversive agents into transdermal patches.
How does the Nutriband™ trademark benefit the company?
The trademark protection enhances Nutriband’s brand recognition and secures their innovation in pharmaceutical research.
What is the significance of the FDA approval for AVERSA™ Fentanyl?
FDA approval is crucial for marketing AVERSA™ Fentanyl and assures safety and efficacy for consumers.
What are the market prospects for AVERSA™ Fentanyl?
Market analysis suggests AVERSA™ Fentanyl could see U.S. sales between $80 million to $200 million annually.
How can interested parties learn more about Nutriband?
Additional information about Nutriband can be found on their official website or by contacting them directly.
